China Biopharmaceuticals (01177): TQB3142 "Bcl-xL PROTAC" clinical trial application accepted by NMPA

Zhijing Finance APP News, China Biopharmaceuticals (01177) announced that the group's independently developed innovative drug TQB3142 "Bcl-xL PROTAC (protein degradation targeted chimeric)" has received acceptance of the new drug clinical trial application (IND) from the National Medical Products Administration (NMPA) of China, and is intended to be used for the treatment of malignant tumors.